Skin Tissue Replacement-Business Plan

Skin Tissue Replacement-Business Plan - SKIN TISSUE...

Info iconThis preview shows pages 1–4. Sign up to view the full content.

View Full Document Right Arrow Icon
SKIN TISSUE REPLACEMENT Business Plan Business Goal: Our goal is the production of new allograft RepliDerm by RepliDerm INC. for the treatment of burn victims. The objective is to initially obtain research grant for research and development of our product RepliDerm. The figure below shows our major competitors in the market and the share of market they hold. As shown in Figure 6, we will capture some part of the market share available for the product. Competitiors' share in market Source of figure : Medtech Insight, LLC. Genzyme tissue repair LifeCell Integra LifeScience 50% 20% 30% TOTAL SALE= $10.2M Figure 6: Market competitors The prime sources of funding will be NIH, SBIR and STTR. There will be some personal contribution to the initial investment. Initially our production rate will be 60,000
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
sheets per month (based from our competitor’s financial information 12 . Our major competitors in skin tissue replacement are LifeCell’s Allorderm template 13 , Genzyme’s Epicel and LifeScience’s Integra. General Infromation: As mentioned earlier, our project will start on researching in laboratory. After certain promising result is obtained, we will apply for government grant for a further research. Once a viable solution is found, we will submit our proposal to FDA to proceed phase 1 testing. After passing the first phase, a major fund raising will be needed since phase 2 and 3 is extremely costly. We will introduce our idea and testing result from phase 1 to convince investors the possibility of the project. With this funding, we will expand our company and initiate phase 2 and 3. We expect the entire project will last for about 10 years. Location of RepliDerm INC. Several locations were considered for headquarters of operation. The list of original selected state for the location is given below. New Jersey Massachusetts California Maryland New York Florida Pennsylvania Ohio Texas Michigan The evaluation for the best location selection was done based on giving importance to each of the factors mentioned above in percentages. NIH funding to each state was given 30% importance in our decision making process. Employment, number of
Background image of page 2
private biotech companies, cost of living, number of hospitals, and corporate tax are given 20%, 15%, 15%, 10% and 10% importance respectively. Research is the most important factor in order for Biotech Company to start and develop. That is why NIH funding to our research project is given the most importance. Employment is second important factor because it contributes significantly to research staff needed for the production of our product. Number of private biotech companies and cost of living in each state were given equal importance because the highest number of biotech companies indicates how a state has been supporting these companies to survive and low cost of living indicates the comparative cost of each state. Number of hospitals and corporate tax rates are the least important in our evaluation however they cannot be ignored because number of hospital in a state will help us survive locally saving cost of marketing. Low
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 4
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 08/31/2011 for the course CHE 4273 taught by Professor Staff during the Spring '10 term at Oklahoma State.

Page1 / 14

Skin Tissue Replacement-Business Plan - SKIN TISSUE...

This preview shows document pages 1 - 4. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online